SILO vs. BIOL, HSCS, SNPX, MYMD, SISI, KTRA, ETAO, CING, KZIA, and MGRX
Should you be buying Silo Pharma stock or one of its competitors? The main competitors of Silo Pharma include BIOLASE (BIOL), Heart Test Laboratories (HSCS), Synaptogenix (SNPX), MyMD Pharmaceuticals (MYMD), Shineco (SISI), Kintara Therapeutics (KTRA), ETAO International (ETAO), Cingulate (CING), Kazia Therapeutics (KZIA), and Mangoceuticals (MGRX). These companies are all part of the "medical" sector.
BIOLASE (NASDAQ:BIOL) and Silo Pharma (NASDAQ:SILO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.
BIOLASE received 288 more outperform votes than Silo Pharma when rated by MarketBeat users. However, 100.00% of users gave Silo Pharma an outperform vote while only 55.36% of users gave BIOLASE an outperform vote.
8.8% of BIOLASE shares are owned by institutional investors. Comparatively, 5.6% of Silo Pharma shares are owned by institutional investors. 0.0% of BIOLASE shares are owned by company insiders. Comparatively, 5.6% of Silo Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
BIOLASE has a net margin of -43.56% compared to BIOLASE's net margin of -4,992.30%. BIOLASE's return on equity of -48.16% beat Silo Pharma's return on equity.
BIOLASE currently has a consensus price target of $75.20, indicating a potential upside of 47,285.00%. Silo Pharma has a consensus price target of $10.00, indicating a potential upside of 431.91%. Given Silo Pharma's higher probable upside, equities analysts clearly believe BIOLASE is more favorable than Silo Pharma.
In the previous week, BIOLASE had 8 more articles in the media than Silo Pharma. MarketBeat recorded 13 mentions for BIOLASE and 5 mentions for Silo Pharma. Silo Pharma's average media sentiment score of 0.33 beat BIOLASE's score of -0.02 indicating that BIOLASE is being referred to more favorably in the media.
BIOLASE has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, Silo Pharma has a beta of 0.12, meaning that its share price is 88% less volatile than the S&P 500.
Silo Pharma has lower revenue, but higher earnings than BIOLASE.
Summary
BIOLASE beats Silo Pharma on 8 of the 14 factors compared between the two stocks.
Get Silo Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for SILO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SILO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Silo Pharma Competitors List
Related Companies and Tools
